logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Alwin D. R. Huitema

Netherlands Cancer Institute
H指数:67
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial

更正：拉帕替尼、比尼米替尼和长春瑞滨治疗RAS突变型转移性结直肠癌的安全性与有效性：RASTRIC I/II期试验结果

British Journal of Cancer
IF6.8
2026-09-250
PRE
Maarten A. Huismans; Eelke H. Gort; Lisa T. van der Heijden; Sermin M. Guven Mese; Helena M. Klein Wolterink; Manon N. G. J. A. Braat; Sjoerd G. Elias; Filip Y. F. L. de Vos; Lot A. Devriese; Henk M. W. Verheul; Frans L. Opdam; Miriam Koopman; Hilde H. Nienhuis; Heleen A. Crommelin; Hugo J. G. Snippert; Alwin D. R. Huitema; Jeanine M. L. Roodhart
Brief report: Reducing Lorlatinib-related Adverse Events by establishing the Optimal Exposure-Toxicity Threshold in Patients with NSCLC

简报：通过建立最优暴露-毒性阈值来降低NSCLC患者Lorlatinib相关不良反应

Journal of Thoracic Oncology
IF20.8
2026-07-160
OAAI
Daan A.C. Lanser; Lisanne N. van Merendonk; G.D.Marijn Veerman; Salomé van Beusekom; Esther Oomen-de Hoop; Peter de Bruijn; Attila Icli; Marthe S. Paats; Alwin D.R. Huitema; Ron H.N. van Schaik; Sushil Badrising; Anne-Marie C. Dingemans; Ron H.J. Mathijssen
The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer

SHERPA试验：一项I期研究，探讨SHP2抑制剂RMC-4630与ERK抑制剂LY3214996联合治疗KRAS突变型胰腺癌、非小细胞肺癌和结直肠癌患者的疗效

European Journal of Cancer
IF7.1
2026-05-060
PRE
Ashwini C. Kanhailal; Jonathan E. Knikman; Sybrand W.J. Zielhuis; Liudmila L. Kodach; René Bernards; Alwin D.R. Huitema; Matthijs Tibben; Emile E. Voest; Brent M. Gerrits; Hinke Huisman-Siebinga; Neeltje Steeghs; Sara Mainardi; Frans L. Opdam
Population Pharmacokinetics of Total and Protein-Unbound Prednisolone in Children with Immune-Mediated and Systemic Inflammatory Diseases

总及蛋白未结合型泼尼松龙的儿童群体药代动力学研究：用于免疫介导性和全身性炎症疾病的患者

Clinical Pharmacokinetics
IF4
2025-12-110
OAAI
Julia E. Möhlmann; Caroline A. Lindemans; Marc H. A. Jansen; Matthijs van Luin; Arjen M. Punt; Solaiman Ezzafzafi; Stefan Nierkens; Alwin D. R. Huitema; Aurelia H. M. de Vries Schultink
Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post-Kala-Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing

利福平阿莫地喹在HIV阳性患者中的药代动力学和药效学：潜在影响和临床意义

Clinical Pharmacology & Therapeutics
IF5.5
2025-11-250
OAAI
Wan-Yu Chu; Om Prakash Singh; Shyam Sundar; Dinesh Mondal; Krishna Pandey; Pradeep Das; Ignace C. Roseboom; Sheeraz Raja; Ana Torres; Eugenia Carrillo; Alwin D.R. Huitema; Fabiana Alves; Thomas P.C. Dorlo
Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof-of-Concept Study with Alectinib

使用稳定同位素标记的微示踪剂减轻癌症患者药物相互作用研究负担：一项关于Alectinib的可行性研究

CLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
2025-11-010
OAAI
Mohmaed Ali, Ma Ida; van der Heijden, Lisa T.; Tibben, Matthijs; Rosing, Hilde; Kalicharan, Raween; Ruiter, Gerrina; Beijnen, Jos H.; Huisman-siebinga, Hinke; Huitema, Alwin D. R.; Steeghs, Neeltje
Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell tumor post-nephrectomy—A case report

替非司法酰胺替代环磷酰胺在TI-CE方案中的应用：肾切除术后难治性转移性生殖细胞瘤患者的药理学及剂量依据——病例报告

Cancer Chemotherapy and Pharmacology
IF2.3
2025-10-220
OA
Lotte M. G. Hulskotte; Loek A. W. de Jong; Alwin D. R. Huitema; Joost Sijm; Ingrid Desar; Minke Smits; Nielka P. van Erp

研究方向

暂未获取到该数据
J
Jos H. Beijnen
H 指数:129论文数:1,778被引数:7.5万
J
Jan H.M. Schellens
H 指数:111论文数:1,187被引数:5.9万
H
Hilde Rosing
H 指数:64论文数:535被引数:1.7万
N
Neeltje Steeghs
H 指数:48论文数:525被引数:1.2万
T
Thomas P. C. Dorlo
H 指数:33论文数:158被引数:4,163
R
Ron H.J. Mathijssen
H 指数:76论文数:888被引数:2.0万
R
Rob ter Heine
H 指数:34论文数:250被引数:3,605
S
Stijn L.W. Koolen
H 指数:30论文数:257被引数:3,517
B
Bastiaan Nuijen
H 指数:34论文数:169被引数:4,651
J
Jeroen J. M. A. Hendrikx
H 指数:20论文数:78被引数:1,299